Page 144 - COVID-19 COUNTRY REPORT: Moving Beyond Pandemic EDITION 2022

Moving Beyond Pandemic (Edition 2022)

References
1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and Chloroquine effectivelyinhibit
the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res [Internet]. 2020;30(3):269–
71. Available from: https://doi.org/10.1038/s41422-020-0282-0
2. Chew Yan Yee; Lim, Ming Tsuey; Chidambaram, Suresh Kumar; Muhamad Zin, Faizah; Lee,
Christopher Kwok Choong; Goh, Pik Pin CHY. COVID-19 Mortality Review in Malaysia & Updates
on Clinical Management of COVID-19 [Internet]. First. Institute for Clinical Research, NIH, Malaysia;
2020. Available from: https://zenodo.org/record/3903972#.ZBO4p3ZBy3A
3. Chang Chen Jianying Huang, Ping Yin, Zhenshun Cheng, Jianyuan Wu, Song Chen, Yongxi Zhang,
Bo Chen, Mengxin Lu, Yongwen Luo, Lingao Ju, Jingyi Zhang, View ORCID ProfileXinghuan Wang
YZ. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Tria [Internet]. 2020. Available
from: https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v4
4. Chuah CH, Chow TS, Hor CP, Cheng JT, Ker HB, Lee HG, et al. Efficacy of Early Treatment
With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease
2019 (COVID-19): A Randomised, Open-Label Clinical Trial. Clin Infect Dis [Internet]. 2022
Jul;75(1):e432–9. Available from: https://doi.org/10.1093/cid/ciab962
5. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits
the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020;178:104787. Available from:
https://www.sciencedirect.com/science/article/pii/S0166354220302011
6. Ang ZY Fun WH, Cheah KY, Shahkirah MS, Kong TL, Balqis-Ali NZ, Selvarajah S., Sarakas S AS.
The 5th COVID-19 Chronicles in Malaysia. Revitalising Recovery [Internet]. National Institute of
Health, Malaysia; 2019. Available from: http://library.nih.gov.my/e-doc/flipbook/ipsk/covid19-
chronicles-malaysia-revitalising-recovery/index.html
7. Reporters FMT. Ronapreve for treatment and prevention of COVID-19 given conditional
approval. FMT [Internet]. 2021; Available from: https://www.freemalaysiatoday.com/category/
nation/2021/12/14/ronapreve-for-treatment-prevention-of-COVID-19-given-conditional-approval/
8. Ronapreve [Internet]. European Medicines Agency. 2021. Available from: https://www.ema.
europa.eu/en/medicines/human/EPAR/ronapreve
9. Kementerian Kementerian Kesihatan Malaysia (MOH). KEPUTUSAN MESYUARAT PIHAK
BERKUASA KAWALAN DADAH KALI KE-370 BERKENAAN PENDAFTARAN PRODUK BAGI
RAWATAN COVID-19 [Internet]. 2022. Available from: https://COVID-19.moh.gov.my/semasa-
kkm/2022/03/keputusan-mesyuarat-pihak-berkuasa-kawalan-dadah-kali-ke-370-berkenaan-
pendaftaran-produk-bagi-rawatan-COVID-19
10. Kementerian Kesihatan Malaysia (MOH). Surat Pekeliling Ketua Pengarah Kesihatan Malaysia
Bil 16 Tahun 2022 Garis Panduan Peluasan Penggunaan Rawatan Ubat Antiviral COVID-19 Bagi
Fasiliti/Pengamal Perubatan Swast [Internet]. 2022. Available from: https://COVID-19.moh.gov.
my/garis-panduan/pekeliling-dan-polisi-rasmi-kkm/Surat_Pekeliling_KPK_Bil_16-2022_Garis_
Panduan_Peluasan_Penggunaan_Rawatan_Antiviral_Ke_Fasiliti_Swasta.pdf
11. Malaysia KK, Ang ZY Fun WH, Cheah KY, Shahkirah MS, Kong TL, Balqis-Ali NZ, Selvarajah S.,
Sarakas S AS, Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, et al. Kenyataan Akhbar KPK 7 April
2022 – Keputusan Mesyuarat Pihak Berkuasa Kawalan Dadah Kali Ke-371 Berkenaan Pendaftaran
Produk Bagi Rawatan COVID-19 [Internet]. First. Vol. 295, From the Desk of the Director-General
of Health Malaysia. Malaysia: Institute for Health Systems Research; 2022 [cited 2022 Feb 16].
p. 22. Available from: https://kpkesihatan.com/2022/04/07/kenyataan-akhbar-kpk-7-april-2022-
keputusan-mesyuarat-pihak-berkuasa-kawalan-dadah-kali-ke-371-berkenaan-pendaftaran-
produk-bagi-rawatan-COVID-19/
12. Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z. Baricitinib, a drug with potential effect to prevent
SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int
Immunopharmacol. 2020 Sep;86:106749.
13. Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients
with COVID-19: A meta-analysis of randomised controlled trials. eClinicalMedicine [Internet]. 2022
Jul;49:101489. Available from: https://linkinghub.elsevier.com/retrieve/pii/S258953702200219X
14. National Institutes of Health. Molnupiravir (September 26, 2022) [Internet]. COVID-19 Treatment
Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2022 [cited 2022 16
February]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-
including-antibody-products/molnupiravir/

134 Chapter 6 -Evolution of COVID-19 Patient Management